ES2608046T3 - Tratamiento de enfermedades asociadas al uso de antibióticos - Google Patents

Tratamiento de enfermedades asociadas al uso de antibióticos Download PDF

Info

Publication number: ES2608046T3
Authority: ES; Spain
Prior art keywords: compound; paragraph; antibiotics; administered; treatment
Prior art date: 2004-05-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES10075449.8T

Other languages

English (en)

Spanish (es)

Inventor

Youe-Kong Shue

Farah Kondori Babakhani

Franklin W. Okumu

Pamela Suzanne Sears

Starr Louise Miller-Shangle

Robert Brian Walsh

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Organon Pharma UK Ltd

Merck Sharp and Dohme LLC

Original Assignee

Merck Sharp and Dohme Ltd

Merck Sharp and Dohme LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-14

Filing date

2005-05-13

Publication date

2017-04-05

2005-05-13 Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd

2017-04-05 Application granted granted Critical

2017-04-05 Publication of ES2608046T3 publication Critical patent/ES2608046T3/es

2025-05-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)

ES10075449.8T 2004-05-14 2005-05-13 Tratamiento de enfermedades asociadas al uso de antibióticos Expired - Lifetime ES2608046T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57069704P	2004-05-14	2004-05-14
US570697P		2004-05-14

Publications (1)

Publication Number	Publication Date
ES2608046T3 true ES2608046T3 (es)	2017-04-05

Family

ID=35428857

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
ES10075449.8T Expired - Lifetime ES2608046T3 (es)	2004-05-14	2005-05-13	Tratamiento de enfermedades asociadas al uso de antibióticos
ES05748007T Expired - Lifetime ES2395404T3 (es)	2004-05-14	2005-05-13	Tratamiento de las enfermedades asociadas al uso de antibióticos
ES10075450T Expired - Lifetime ES2713954T3 (es)	2004-05-14	2005-05-13	Tratamiento de enfermedades asociadas al uso de antibióticos
ES09156339.5T Expired - Lifetime ES2565609T3 (es)	2004-05-14	2005-05-13	Tratamiento de enfermedades asociadas al uso de antibióticos

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
ES05748007T Expired - Lifetime ES2395404T3 (es)	2004-05-14	2005-05-13	Tratamiento de las enfermedades asociadas al uso de antibióticos
ES10075450T Expired - Lifetime ES2713954T3 (es)	2004-05-14	2005-05-13	Tratamiento de enfermedades asociadas al uso de antibióticos
ES09156339.5T Expired - Lifetime ES2565609T3 (es)	2004-05-14	2005-05-13	Tratamiento de enfermedades asociadas al uso de antibióticos

Country Status (17)

Country	Link
US (2)	US20070173462A1 (pl)
EP (4)	EP2305244B1 (pl)
JP (2)	JP5734545B2 (pl)
AT (1)	ATE516024T1 (pl)
BR (1)	BRPI0511119A (pl)
CA (2)	CA2776682A1 (pl)
CY (2)	CY1117501T1 (pl)
DK (3)	DK2305244T3 (pl)
ES (4)	ES2608046T3 (pl)
HU (3)	HUE031581T2 (pl)
LT (1)	LT2305245T (pl)
MX (2)	MXPA06013245A (pl)
PL (3)	PL2070530T3 (pl)
PT (2)	PT2305244T (pl)
SI (2)	SI2305245T1 (pl)
TR (1)	TR201902533T4 (pl)
WO (1)	WO2005112990A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7906489B2 (en)	2004-05-14	2011-03-15	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
CN102614207B (zh) *	2005-01-31	2016-01-13	默克夏普&多梅有限公司	18元环大环化合物及其类似物
US7378508B2 (en)	2007-01-22	2008-05-27	Optimer Pharmaceuticals, Inc.	Polymorphic crystalline forms of tiacumicin B
CN102503994A (zh) *	2005-10-21	2012-06-20	奥普蒂姆药物公司	治疗艰难梭菌相关的腹泻的方法
TWI523654B (zh)	2007-11-27	2016-03-01	默沙東藥廠	抗生素巨環化合物以及其製造及使用之方法
US20110008303A1 (en) *	2008-03-17	2011-01-13	Cedars-Sinai Medical Center	Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) *	2009-10-06	2011-04-14	Scott Dorfner	Antibiotic formulations providing reduced gastrointentestinal side effects
AU2010320558A1 (en) *	2009-11-17	2012-07-12	Piramal Enterprises Limited	Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
AU2010339573B2 (en) *	2009-12-31	2014-08-28	Ira Milton Trachtman	Compositions and method for treatment and prophylaxis of inflammatory bowel disease
PE20130310A1 (es) *	2010-05-18	2013-04-06	Optimer Pharmaceuticals Inc	Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
CA2948400A1 (en) *	2014-05-09	2015-11-12	Astellas Pharma Europe Ltd	Treatment regimen tiacumicin compound
AU2018379996A1 (en)	2017-12-05	2020-06-25	BioPlx, Inc.	Methods and compositions to prevent microbial infection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3279995A (en)	1963-05-31	1966-10-18	Allen F Reid	Shaped pellets
GB1458512A (en) *	1973-11-22	1976-12-15	Lepetit Spa	Antibiotic substance
US4111202A (en)	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for the controlled and delivery of agent over time
US4918174A (en)	1986-09-26	1990-04-17	Abbott Laboratories	Tiacumicin compounds
US4786503A (en)	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
US5443841A (en)	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en)	1992-04-24	2001-05-22	Brown University Research Foundation	Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) *	1995-05-09	1996-12-10	Abbott Laboratories	Dialkyltiacumicin compounds
US6143211A (en)	1995-07-21	2000-11-07	Brown University Foundation	Process for preparing microparticles through phase inversion phenomena
US5767096A (en) *	1996-07-12	1998-06-16	Abbott Laboratories	Bromotiacumicin compounds
IN186245B (pl)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
PT1527100E (pt) *	2002-03-29	2009-08-25	Schering Corp	Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
WO2004014295A2 (en) *	2002-07-29	2004-02-19	Optimer Pharmaceuticals, Inc.	Tiacumicin production
US20070105791A1 (en) *	2002-07-29	2007-05-10	Optimer Pharmaceuticals, Inc.	Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) *	2004-05-14	2011-03-15	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7378508B2 (en) *	2007-01-22	2008-05-27	Optimer Pharmaceuticals, Inc.	Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) *	2007-01-22	2010-10-27	Optimer Pharmaceuticals Inc	Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) *	2007-11-27	2016-03-01	默沙東藥廠	抗生素巨環化合物以及其製造及使用之方法

2005
- 2005-05-13 HU HUE10075449A patent/HUE031581T2/en unknown
- 2005-05-13 MX MXPA06013245A patent/MXPA06013245A/es active IP Right Grant
- 2005-05-13 CA CA2776682A patent/CA2776682A1/en not_active Withdrawn
- 2005-05-13 PL PL09156339T patent/PL2070530T3/pl unknown
- 2005-05-13 US US11/596,340 patent/US20070173462A1/en not_active Abandoned
- 2005-05-13 PL PL10075449T patent/PL2305244T3/pl unknown
- 2005-05-13 WO PCT/US2005/016750 patent/WO2005112990A2/en not_active Ceased
- 2005-05-13 SI SI200532245T patent/SI2305245T1/sl unknown
- 2005-05-13 MX MX2014003990A patent/MX344601B/es unknown
- 2005-05-13 EP EP10075449.8A patent/EP2305244B1/en not_active Expired - Lifetime
- 2005-05-13 DK DK10075449.8T patent/DK2305244T3/en active
- 2005-05-13 JP JP2007513392A patent/JP5734545B2/ja not_active Expired - Lifetime
- 2005-05-13 PT PT100754498T patent/PT2305244T/pt unknown
- 2005-05-13 DK DK09156339.5T patent/DK2070530T3/da active
- 2005-05-13 ES ES10075449.8T patent/ES2608046T3/es not_active Expired - Lifetime
- 2005-05-13 EP EP10075450.6A patent/EP2305245B1/en not_active Expired - Lifetime
- 2005-05-13 EP EP05748007A patent/EP1765312B1/en not_active Expired - Lifetime
- 2005-05-13 PL PL10075450T patent/PL2305245T3/pl unknown
- 2005-05-13 HU HUE10075450A patent/HUE043945T2/hu unknown
- 2005-05-13 SI SI200532054A patent/SI2070530T1/sl unknown
- 2005-05-13 ES ES05748007T patent/ES2395404T3/es not_active Expired - Lifetime
- 2005-05-13 AT AT05748007T patent/ATE516024T1/de not_active IP Right Cessation
- 2005-05-13 HU HUE09156339A patent/HUE027757T2/en unknown
- 2005-05-13 TR TR2019/02533T patent/TR201902533T4/tr unknown
- 2005-05-13 ES ES10075450T patent/ES2713954T3/es not_active Expired - Lifetime
- 2005-05-13 PT PT10075450T patent/PT2305245T/pt unknown
- 2005-05-13 LT LTEP10075450.6T patent/LT2305245T/lt unknown
- 2005-05-13 CA CA2566687A patent/CA2566687C/en not_active Expired - Lifetime
- 2005-05-13 EP EP09156339.5A patent/EP2070530B1/en not_active Expired - Lifetime
- 2005-05-13 DK DK10075450.6T patent/DK2305245T3/en active
- 2005-05-13 BR BRPI0511119-6A patent/BRPI0511119A/pt not_active IP Right Cessation
- 2005-05-13 ES ES09156339.5T patent/ES2565609T3/es not_active Expired - Lifetime
2012
- 2012-04-26 US US13/457,216 patent/US20130274175A1/en not_active Abandoned
- 2012-06-19 JP JP2012138170A patent/JP6101010B2/ja not_active Expired - Lifetime
2016
- 2016-05-13 CY CY20161100404T patent/CY1117501T1/el unknown
2019
- 2019-02-28 CY CY20191100248T patent/CY1121284T1/el unknown

Also Published As

Publication number	Publication date
HUE043945T2 (hu)	2019-09-30
EP1765312A2 (en)	2007-03-28
EP1765312B1 (en)	2011-07-13
JP2012197309A (ja)	2012-10-18
DK2305245T3 (en)	2019-03-25
PL2305244T3 (pl)	2017-04-28
HUE031581T2 (en)	2017-07-28
HUE027757T2 (en)	2016-11-28
CA2566687C (en)	2012-07-24
TR201902533T4 (tr)	2019-03-21
EP2305245B1 (en)	2019-01-02
CY1121284T1 (el)	2020-05-29
US20070173462A1 (en)	2007-07-26
WO2005112990A3 (en)	2006-01-05
ES2565609T3 (es)	2016-04-05
EP1765312A4 (en)	2007-08-22
JP5734545B2 (ja)	2015-06-17
DK2070530T3 (da)	2016-05-17
ES2395404T3 (es)	2013-02-12
EP2070530B1 (en)	2016-02-17
PL2305245T3 (pl)	2019-05-31
MX344601B (es)	2016-12-20
ES2713954T3 (es)	2019-05-24
EP2305245A1 (en)	2011-04-06
EP2070530A1 (en)	2009-06-17
DK2305244T3 (en)	2017-01-30
WO2005112990A2 (en)	2005-12-01
PL2070530T3 (pl)	2016-06-30
ATE516024T1 (de)	2011-07-15
SI2305245T1 (sl)	2019-04-30
JP2007537290A (ja)	2007-12-20
MXPA06013245A (es)	2007-05-09
CY1117501T1 (el)	2017-04-26
LT2305245T (lt)	2019-03-12
US20130274175A1 (en)	2013-10-17
BRPI0511119A (pt)	2007-11-27
SI2070530T1 (sl)	2016-05-31
PT2305244T (pt)	2016-12-29
CA2776682A1 (en)	2005-12-01
CA2566687A1 (en)	2005-12-01
JP6101010B2 (ja)	2017-03-22
EP2305244B1 (en)	2016-10-12
EP2305244A1 (en)	2011-04-06
PT2305245T (pt)	2019-03-19

Publication	Publication Date	Title
ES2608046T3 (es)	2017-04-05	Tratamiento de enfermedades asociadas al uso de antibióticos
JP5469511B2 (ja)	2014-04-16	微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
Musgrave et al.	2011	Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection
US20040106590A1 (en)	2004-06-03	Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
US20040147441A1 (en)	2004-07-29	Methods and reagents for preventing bacteremias
CN102215858A (zh)	2011-10-12	使用单剂量奥利万星的治疗方法
US10758529B2 (en)	2020-09-01	Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity
KR20110059725A (ko)	2011-06-03	세프타롤린을 포함하는 조성물 및 치료 방법
MacGowan et al.	2013	Frontline antibiotic therapy
Karageorgopoulos et al.	2009	New antibiotics: optimal use in current clinical practice
JP2018526455A (ja)	2018-09-13	抗生物質療法
PT1458391E (pt)	2007-12-10	Um processo para tratamento de infecções bacterianas através do uso de gemifloxacina ou um seu sal e um antibiótico b-lactâmico
HK1155947A (en)	2012-06-01	Treatment of diseases associated with the use of antibiotics
HK1155983A (en)	2012-06-01	Treatment of diseases associated with the use of antibiotics